Bob Johnson
CH.com Alumnus
 
Offline

"Only the educated are free." -Epictetus
Posts: 5965
Kennett Square, PA (USA)
Gender:
|
One of the joys of this place is that we keep reinventing the wheel!
Years ago, the use of heat and/or cold was a regular topic here. No much else useful then but, with the introduction of the triptans, etc., this subject has largely disppeared.
But it's super that you have found relief!
Might consider using Frova for its longer usefl life. ---- Expert Opin Drug Metab Toxicol. 2011 Sep 20. Pharmacokinetic evaluation of frovatriptan. Negro A, Lionetto L, Casolla B, Lala N, Simmaco M, Martelletti P. SourceSapienza University, Regional Referral Headache Center, School of Health Sciences , Department of Medical and Molecular Sciences, Rome , Italy. Abstract Introduction: Migraine is the most common painful neurological disorder, affecting 13% of the general population. Triptans represent a powerful pharmacological tool in acute migraine treatment, however, a significant portion of treated patients cannot have access to this class due to possible adverse affects. Today, a total of seven triptan molecules are available, representing a commonly prescribed migraine treatment. Although there is a need of extensive use of triptans, only 25% of migraine patients are using triptans. Areas covered: This review includes triptans and evidence for the use of frovatriptan. A systematic approach is used to discuss the pharmacodynamic and pharmacokinetic aspects of frovatriptan, considering the emerging data on the clinical efficacy of frovatriptan in the treatment of migraine and cluster headaches. The data were obtained by searching the following key words in MEDLINE: pharmacokinetic, pharmacodynamic, triptans, frovatriptan, migraine, menstrual migraine, relatively to the period 1988 - 2011. Expert opinion: Frovatriptan has been developed in order to improve safety and efficacy of triptans. It shows a favorable tolerability and efficacy profile, limited to 24/48-h headache recurrence, when compared with other triptans. Preclinical data suggest that the pharmacokinetic profile of frovatriptan may differ from other available triptans. IN FACT, AMONG TRIPTANS, FROVATRIPTAN SHOWED THE HIGHEST POTENCY AT THE 5-HT1B RECEPTOR (8.2) AND THE LONGER HALF-LIFE (26 H). THESE PARAMETERS DETERMINE THE CLINICAL PROPERTIES OF FROVATRIPTAN; IN PARTICULAR THE LOWEST RATE OF HEADACHE RECURRENCE IN COMPARISON WITH OTHER TRIPTANS. PMID:21929465[PubMed]
|